These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

952 related items for PubMed ID: 15243933

  • 1. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
    Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM.
    J Infect Dis; 2004 Aug 01; 190(3):565-70. PubMed ID: 15243933
    [Abstract] [Full Text] [Related]

  • 2. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
    Pakkanen SH, Kantele JM, Savolainen LE, Rombo L, Kantele A.
    Vaccine; 2015 Jan 09; 33(3):451-8. PubMed ID: 25433216
    [Abstract] [Full Text] [Related]

  • 3. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909.
    Wang JY, Noriega FR, Galen JE, Barry E, Levine MM.
    Infect Immun; 2000 Aug 09; 68(8):4647-52. PubMed ID: 10899868
    [Abstract] [Full Text] [Related]

  • 4. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings.
    Zhou WZ, Koo HW, Wang XY, Zhang J, Park JK, Zhu F, Deen J, Acosta CJ, Chen Y, Wang H, Galindo CM, Ochiai L, Park T, von Seidlein L, Xu ZY, Clemens JD.
    Pediatr Infect Dis J; 2007 Nov 09; 26(11):1001-5. PubMed ID: 17984806
    [Abstract] [Full Text] [Related]

  • 5. Vi Capsular Polysaccharide Produced by Recombinant Salmonella enterica Serovar Paratyphi A Confers Immunoprotection against Infection by Salmonella enterica Serovar Typhi.
    Xiong K, Zhu C, Chen Z, Zheng C, Tan Y, Rao X, Cong Y.
    Front Cell Infect Microbiol; 2017 Nov 09; 7():135. PubMed ID: 28484685
    [Abstract] [Full Text] [Related]

  • 6. A review of the current status of enteric vaccines.
    Levine MM, Noriega F.
    P N G Med J; 1995 Dec 09; 38(4):325-31. PubMed ID: 9522876
    [Abstract] [Full Text] [Related]

  • 7. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae.
    Pakkanen SH, Kantele JM, Herzog C, Kantele A.
    Vaccine; 2014 Jan 23; 32(5):544-51. PubMed ID: 24342246
    [Abstract] [Full Text] [Related]

  • 8. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations.
    Kirkpatrick BD, Tenney KM, Larsson CJ, O'Neill JP, Ventrone C, Bentley M, Upton A, Hindle Z, Fidler C, Kutzko D, Holdridge R, Lapointe C, Hamlet S, Chatfield SN.
    J Infect Dis; 2005 Aug 01; 192(3):360-6. PubMed ID: 15995948
    [Abstract] [Full Text] [Related]

  • 9. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.
    Darton TC, Jones C, Blohmke CJ, Waddington CS, Zhou L, Peters A, Haworth K, Sie R, Green CA, Jeppesen CA, Moore M, Thompson BA, John T, Kingsley RA, Yu LM, Voysey M, Hindle Z, Lockhart S, Sztein MB, Dougan G, Angus B, Levine MM, Pollard AJ.
    PLoS Negl Trop Dis; 2016 Aug 01; 10(8):e0004926. PubMed ID: 27533046
    [Abstract] [Full Text] [Related]

  • 10. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.
    Wahid R, Pasetti MF, Maciel M, Simon JK, Tacket CO, Levine MM, Sztein MB.
    Clin Immunol; 2011 Feb 01; 138(2):187-200. PubMed ID: 21146460
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M, Shah N, Ghosh A, Chatterjee S, Kaur I, Bhattacharya N, Basu S.
    Hum Vaccin Immunother; 2016 Apr 02; 12(4):939-45. PubMed ID: 26901576
    [Abstract] [Full Text] [Related]

  • 12. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
    Ni Y, Springer MJ, Guo J, Finger-Baker I, Wilson JP, Cobb RR, Turner D, Tizard I.
    Vaccine; 2017 Dec 18; 35(51):7121-7126. PubMed ID: 29150208
    [Abstract] [Full Text] [Related]

  • 13. Live oral typhoid vaccine Salmonella Typhi Ty21a - a surrogate vaccine against non-typhoid salmonella?
    Kantele A, Pakkanen SH, Siitonen A, Karttunen R, Kantele JM.
    Vaccine; 2012 Nov 26; 30(50):7238-45. PubMed ID: 23084770
    [Abstract] [Full Text] [Related]

  • 14. Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya.
    Mirza NB, Wamola IA, Estambale BA, Mbithi E, Poillet M.
    East Afr Med J; 1995 Mar 26; 72(3):162-4. PubMed ID: 7796767
    [Abstract] [Full Text] [Related]

  • 15. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
    Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, Dutta S, Donner A, Kanungo S, Park JK, Puri MK, Kim DR, Dutta D, Bhaduri B, Acosta CJ, Clemens JD.
    N Engl J Med; 2009 Jul 23; 361(4):335-44. PubMed ID: 19625715
    [Abstract] [Full Text] [Related]

  • 16. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
    Klugman KP, Gilbertson IT, Koornhof HJ, Robbins JB, Schneerson R, Schulz D, Cadoz M, Armand J.
    Lancet; 1987 Nov 21; 2(8569):1165-9. PubMed ID: 2890805
    [Abstract] [Full Text] [Related]

  • 17. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial.
    Kantele A, Pakkanen SH, Karttunen R, Kantele JM.
    PLoS One; 2013 Nov 21; 8(4):e60583. PubMed ID: 23593253
    [Abstract] [Full Text] [Related]

  • 18. Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever.
    Froeschle JE, Decker MD.
    Vaccine; 2010 Feb 10; 28(6):1451-3. PubMed ID: 20003920
    [Abstract] [Full Text] [Related]

  • 19. Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies.
    Tacket CO, Losonsky G, Taylor DN, Baron LS, Kopecko D, Cryz S, Levine MM.
    J Infect Dis; 1991 Apr 10; 163(4):901-4. PubMed ID: 2010645
    [Abstract] [Full Text] [Related]

  • 20. Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors.
    Levine MM, Galen J, Barry E, Noriega F, Chatfield S, Sztein M, Dougan G, Tacket C.
    J Biotechnol; 1996 Jan 26; 44(1-3):193-6. PubMed ID: 8717403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.